Oxford spinout Evox grabs a $45M bankroll to advance to the clinic with new exosome tech
A group of scientists intent on hijacking exosomes for therapeutic purposes has gathered together a $45.4 million round — including a significant contribution from Google’s GV — to back their move toward the clinic with new drugs for rare diseases.
The biotech is called Evox Therapeutics. Based in Oxford, the company has positioned itself among the handful of players that are using tiny exosomes — part of the body’s natural vesicle courier system — to deliver a therapeutic payload where needed, including targets in the brain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
